Tate & Lyle PLC
5 April 2005 - Tate & Lyle PLC
TATE & LYLE BOARD CHANGE
Tate & Lyle PLC announces today that Dr. Barry L. Zoumas has been appointed as a
Non-Executive Director with effect from 1 May 2005.
Dr. Zoumas, aged 62, is the Alan R. Warehime Professor of Agribusiness and
Professor of Food Science and Nutrition at The Pennsylvania State University. In
addition, he is President of the International Life Sciences Institute, North
American Branch, of which he is also a Director. He is based in the USA.
Dr. Zoumas worked for Hershey Foods Corporation for 27 years, the last sixteen
as Corporate Vice President, Science and Technology with responsibility for R&D,
Corporate Engineering, Quality Assurance, Agribusiness and Regulatory Affairs.
He has extensive international experience having previously served as Visiting
Scientist for the Rome-based Food and Agriculture Organization of the United
Nations and as a Principal Advisor to US Aid for Agricultural Development. He
sits on a wide range of major committees and associations impacting the food
business, holds a number of important scientific awards and has a range of
publications and US patents to his name.
Sir David Lees, Chairman of Tate & Lyle, said 'I am delighted that Dr. Zoumas is
to join the Board as a Non-Executive Director. His background as a scientist and
businessman will add diversity and strength to the Board and offer an important
perspective on our business development.'
CONTACTS
Chris Fox, Director of Corporate Relations (Press) Tel: 020 7626 6525 or Mobile:
07801 808553
Mark Robinson, Head of Investor Relations Tel: 020 7626 6525 or Mobile: 07793
515861 investorrelations@tateandlyle.com
Tate & Lyle is a world leading manufacturer of renewable food and industrial
ingredients. It uses innovative technology to transform corn, wheat and sugar
into value-added ingredients for customers in the food, beverage,
pharmaceutical, cosmetic, paper, packaging and building industries. The Company
is a leader in cereal sweeteners and starches, sugar refining, value added food
and industrial ingredients, and citric acid. Tate & Lyle is the world number-one
in industrial starches and is the sole manufacturer of SPLENDA® Sucralose.
Headquartered in London, Tate & Lyle is listed on the London Stock Exchange
under the symbol TATE.L. In the US its ADRs trade under TATYY. The Company
operates more than 60 production facilities in 28 countries, throughout Europe,
the Americas and South East Asia. It employs 6,700 people in its subsidiaries
with a further 4,800 employed in joint ventures. Sales in the year to 31 March
2004 totalled £3.1 billion. Additional information can be found on
www.tateandlyle.com.
SPLENDA® is a trademark of McNeil Nutritionals¸ LLC
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.